

BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

Chris Holt, M.D.

Physician's & Surgeon's
Certificate No. A 96213

Case No. 800-2017-039244

Respondent.

DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on July 29, 2021.

IT IS SO ORDERED: June 29, 2021.

MEDICAL BOARD OF CALIFORNIA



Ronald H. Lewis, M.D., Chair
Panel A

1 ROB BONTA
Attorney General of California
2 ALEXANDRA M. ALVAREZ
Supervising Deputy Attorney General
3 KAROLYN M. WESTFALL
Deputy Attorney General
4 State Bar No. 234540
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9465
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9
10 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
11 **DEPARTMENT OF CONSUMER AFFAIRS**
12 **STATE OF CALIFORNIA**

13 In the Matter of the Accusation Against:

14 **CHRIS HOLT, M.D.**
15 **3940 4th Ave., Ste. 140**
San Diego, CA 92103-3193

16 **Physician's and Surgeon's Certificate**
17 **No. A 96213,**

18 Respondent.

Case No. 800-2017-039244

OAH No. 2021020109

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER**

19 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
20 entitled proceedings that the following matters are true:

21 **PARTIES**

22 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of
23 California (Board). He brought this action solely in his official capacity and is represented in this
24 matter by Rob Bonta, Attorney General of the State of California, by Karolyn M. Westfall,
25 Deputy Attorney General.

26 2. Respondent Chris Holt, M.D. (Respondent) is represented in this proceeding by
27 attorney David M. Balfour Esq., whose address is: 1925 Palomar Oaks Way, Suite 220
28 Carlsbad, CA 92008.

1 3. On or about June 30, 2006, the Board issued Physician's and Surgeon's Certificate
2 No. A 96213 to Respondent. The Physician's and Surgeon's Certificate was in full force and
3 effect at all times relevant to the charges brought in Accusation No. 800-2017-039244, and will
4 expire on February 28, 2022, unless renewed.

5 4. On or about November 18, 2020, an Interim Order Imposing License Restrictions was
6 issued by the Office of Administrative Hearings, immediately restricting Physician's and
7 Surgeon's Certificate No. A 96213, and requiring Respondent to adhere to specific conditions in
8 order to continue practicing medicine in the State of California. The Interim Order Imposing
9 License Restrictions remains in full force and effect as of the effective date of this Stipulated
10 Settlement and Disciplinary Order.

11 **JURISDICTION**

12 5 Accusation No. 800-2017-039244 was filed before the Board, and is currently
13 pending against Respondent. The Accusation and all other statutorily required documents were
14 properly served on Respondent on December 7, 2020. Respondent timely filed his Notice of
15 Defense contesting the Accusation.

16 6. A copy of Accusation No. 800-2017-039244 is attached as Exhibit A and
17 incorporated herein by reference.

18 **ADVISEMENT AND WAIVERS**

19 7. Respondent has carefully read, fully discussed with counsel, and understands the
20 charges and allegations in Accusation No. 800-2017-039244. Respondent has also carefully read,
21 fully discussed with his counsel, and understands the effects of this Stipulated Settlement and
22 Disciplinary Order.

23 8. Respondent is fully aware of his legal rights in this matter, including the right to a
24 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine
25 the witnesses against him; the right to present evidence and to testify on his own behalf; the right
26 to the issuance of subpoenas to compel the attendance of witnesses and the production of
27 documents; the right to reconsideration and court review of an adverse decision; and all other
28 rights accorded by the California Administrative Procedure Act and other applicable laws.

1 9. Having the benefit of counsel, Respondent voluntarily, knowingly, and intelligently
2 waives and gives up each and every right set forth above.

3 CULPABILITY

4 10. Respondent does not contest that, at an administrative hearing, Complainant could
5 establish a prima facie case with respect to the charges and allegations contained in Accusation
6 No. 800-2017-039244, and agrees that he has thereby subjected his Physician's and Surgeon's
7 Certificate No. A 96213 to disciplinary action.

8 11. Respondent further agrees that if he ever petitions for modification or early
9 termination of probation, or if an accusation and/or petition to revoke probation is filed against
10 him before the Medical Board of California, all of the charges and allegations contained in
11 Accusation No. 800-2017-039244, shall be deemed true, correct, and fully admitted by
12 Respondent for purposes of any such proceeding or any other licensing proceeding involving
13 Respondent in the State of California.

14 12. Respondent acknowledges the Disciplinary Order below, requiring the disclosure of
15 probation pursuant to Business and Professions Code section 2228.1, serves to protect the public
16 interest.

17 13. Respondent agrees that his Physician's and Surgeon's Certificate No. A 96213 is
18 subject to discipline and he agrees to be bound by the Board's imposition of discipline as set forth
19 in the Disciplinary Order below.

20 CONTINGENCY

21 14. This stipulation shall be subject to approval by the Medical Board of California.
22 Respondent understands and agrees that counsel for Complainant and the staff of the Medical
23 Board of California may communicate directly with the Board regarding this stipulation and
24 settlement, without notice to or participation by Respondent or his counsel. By signing the
25 stipulation, Respondent understands and agrees that he may not withdraw his agreement or seek
26 to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails
27 to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary
28 Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal

1 action between the parties, and the Board shall not be disqualified from further action by having
2 considered this matter.

3 15. The parties understand and agree that Portable Document Format (PDF) and facsimile
4 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile
5 signatures thereto, shall have the same force and effect as the originals.

6 16. In consideration of the foregoing admissions and stipulations, the parties agree that
7 the Board may, without further notice or opportunity to be heard by the Respondent, issue and
8 enter the following Disciplinary Order:

9 **DISCIPLINARY ORDER**

10 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. A 96213 issued
11 to Respondent, Chris Holt, M.D., is revoked. However, the revocation is stayed and Respondent
12 is placed on probation for five (5) years on the following terms and conditions:

13 1. PATIENT DISCLOSURE. Before a patient's first visit following the effective date
14 of this order and while Respondent is on probation, Respondent must provide all patients, or
15 patient's guardian or health care surrogate, with a separate disclosure that includes Respondent's
16 probation status, the length of the probation, the probation end date, all practice restrictions
17 placed on Respondent by the Board, the Board's telephone number, and an explanation of how
18 the patient can find further information on Respondent's probation on Respondent's profile page
19 on the Board's website. Respondent shall obtain from the patient, or the patient's guardian or
20 health care surrogate, a separate, signed copy of that disclosure. Respondent shall not be required
21 to provide a disclosure if any of the following applies: (1) The patient is unconscious or
22 otherwise unable to comprehend the disclosure and sign the copy of the disclosure and a guardian
23 or health care surrogate is unavailable to comprehend the disclosure and sign the copy; (2) The
24 visit occurs in an emergency room or an urgent care facility or the visit is unscheduled, including
25 consultations in inpatient facilities; (3) Respondent is not known to the patient until immediately
26 prior to the start of the visit; (4) Respondent does not have a direct treatment relationship with the
27 patient.

28 ///

1 2. CONTROLLED SUBSTANCES - ABSTAIN FROM USE. Respondent shall abstain
2 completely from the personal use or possession of controlled substances as defined in the
3 California Uniform Controlled Substances Act, dangerous drugs as defined by Business and
4 Professions Code section 4022, and any drugs requiring a prescription. This prohibition does not
5 apply to medications lawfully prescribed to Respondent by another practitioner for a bona fide
6 illness or condition.

7 Within 15 calendar days of receiving any lawfully prescribed medications, Respondent
8 shall notify the Board or its designee of the: issuing practitioner's name, address, and telephone
9 number; medication name, strength, and quantity; and issuing pharmacy name, address, and
10 telephone number.

11 3. ALCOHOL - ABSTAIN FROM USE. Respondent shall abstain completely from the
12 use of products or beverages containing alcohol.

13 4. EDUCATION COURSE. Within 60 calendar days of the effective date of this
14 Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee
15 for its prior approval educational program(s) or course(s) which shall not be less than 40 hours
16 per year, for each year of probation. The educational program(s) or course(s) shall be aimed at
17 correcting any areas of deficient practice or knowledge and shall be Category I certified. The
18 educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to
19 the Continuing Medical Education (CME) requirements for renewal of licensure. Following the
20 completion of each course, the Board or its designee may administer an examination to test
21 Respondent's knowledge of the course. Respondent shall provide proof of attendance for 65
22 hours of CME of which 40 hours were in satisfaction of this condition.

23 5. PROFESSIONALISM PROGRAM (ETHICS COURSE). Within 60 calendar days of
24 the effective date of this Decision, Respondent shall enroll in a professionalism program, that
25 meets the requirements of Title 16, California Code of Regulations (CCR) section 1358.1.
26 Respondent shall participate in and successfully complete that program. Respondent shall
27 provide any information and documents that the program may deem pertinent. Respondent shall
28 successfully complete the classroom component of the program not later than six (6) months after

1 Respondent's initial enrollment, and the longitudinal component of the program not later than the
2 time specified by the program, but no later than one (1) year after attending the classroom
3 component. The professionalism program shall be at Respondent's expense and shall be in
4 addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

5 A professionalism program taken after the acts that gave rise to the charges in the
6 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
7 or its designee, be accepted towards the fulfillment of this condition if the program would have
8 been approved by the Board or its designee had the program been taken after the effective date of
9 this Decision.

10 Respondent shall submit a certification of successful completion to the Board or its
11 designee not later than 15 calendar days after successfully completing the program or not later
12 than 15 calendar days after the effective date of the Decision, whichever is later.

13 6. PSYCHIATRIC EVALUATION. Within 30 calendar days of the effective date of
14 this Decision, and on whatever periodic basis thereafter may be required by the Board or its
15 designee, Respondent shall undergo and complete a psychiatric evaluation (and psychological
16 testing, if deemed necessary) by a Board-appointed board certified psychiatrist, which shall not
17 include his former treating psychiatrist, A.R., and who shall consider any information provided by
18 the Board or designee and any other information the psychiatrist deems relevant, and shall furnish
19 a written evaluation report to the Board or its designee. Psychiatric evaluations conducted prior
20 to the effective date of the Decision shall not be accepted towards the fulfillment of this
21 requirement. Respondent shall pay the cost of all psychiatric evaluations and psychological
22 testing.

23 Respondent shall comply with all restrictions or conditions recommended by the evaluating
24 psychiatrist within 15 calendar days after being notified by the Board or its designee.

25 7. PSYCHOTHERAPY. Within 60 calendar days of the effective date of this Decision,
26 Respondent shall submit to the Board or its designee for prior approval the name and
27 qualifications of a California-licensed board certified psychiatrist or a licensed psychologist who
28 has a doctoral degree in psychology and at least five years of postgraduate experience in the

1 diagnosis and treatment of emotional and mental disorders. Upon approval, Respondent shall
2 undergo and continue psychotherapy treatment, including any modifications to the frequency of
3 psychotherapy, until the Board or its designee deems that no further psychotherapy is necessary.

4 The psychotherapist shall consider any information provided by the Board or its designee
5 and any other information the psychotherapist deems relevant and shall furnish a written
6 evaluation report to the Board or its designee. Respondent shall cooperate in providing the
7 psychotherapist with any information and documents that the psychotherapist may deem
8 pertinent.

9 Respondent shall have the treating psychotherapist submit quarterly status reports to the
10 Board or its designee. The Board or its designee may require Respondent to undergo psychiatric
11 evaluations by a Board-appointed board certified psychiatrist. If, prior to the completion of
12 probation, Respondent is found to be mentally unfit to resume the practice of medicine without
13 restrictions, the Board shall retain continuing jurisdiction over Respondent's license and the
14 period of probation shall be extended until the Board determines that Respondent is mentally fit
15 to resume the practice of medicine without restrictions.

16 Respondent shall pay the cost of all psychotherapy and psychiatric evaluations.

17 8. MEDICAL EVALUATION AND TREATMENT. Within 30 calendar days of the
18 effective date of this Decision, and on a periodic basis thereafter as may be required by the Board
19 or its designee, Respondent shall undergo a medical evaluation by a Board-appointed physician
20 who shall consider any information provided by the Board or designee and any other information
21 the evaluating physician deems relevant and shall furnish a medical report to the Board or its
22 designee. Respondent shall provide the evaluating physician with any information and
23 documentation that the evaluating physician may deem pertinent.

24 Following the evaluation, Respondent shall comply with all restrictions or conditions
25 recommended by the evaluating physician within 15 calendar days after being notified by the
26 Board or its designee. If Respondent is required by the Board or its designee to undergo medical
27 treatment, Respondent shall within 30 calendar days of the requirement notice, submit to the
28 Board or its designee for prior approval the name and qualifications of a California licensed

1 treating physician of Respondent's choice. Upon approval of the treating physician, Respondent
2 shall within 15 calendar days undertake medical treatment and shall continue such treatment until
3 further notice from the Board or its designee.

4 The treating physician shall consider any information provided by the Board or its designee
5 or any other information the treating physician may deem pertinent prior to commencement of
6 treatment. Respondent shall have the treating physician submit quarterly reports to the Board or
7 its designee indicating whether or not the Respondent is capable of practicing medicine safely.
8 Respondent shall provide the Board or its designee with any and all medical records pertaining to
9 treatment that the Board or its designee deems necessary.

10 If, prior to the completion of probation, Respondent is found to be physically incapable of
11 resuming the practice of medicine without restrictions, the Board shall retain continuing
12 jurisdiction over Respondent's license and the period of probation shall be extended until the
13 Board determines that Respondent is physically capable of resuming the practice of medicine
14 without restrictions. Respondent shall pay the cost of the medical evaluation(s) and treatment.

15 9. PROHIBITED PRACTICE. During probation, Respondent is prohibited from from
16 self-prescribing any controlled substances as defined in the California Uniform Controlled
17 Substances Act, any dangerous drugs as defined by Business and Professions Code section 4022,
18 and any drugs requiring a prescription.

19 10. NOTICE OF EMPLOYER OR SUPERVISOR INFORMATION. Within seven (7)
20 days of the effective date of this Decision, Respondent shall provide to the Board the names,
21 physical addresses, mailing addresses, and telephone numbers of any and all employers and
22 supervisors. Respondent shall also provide specific, written consent for the Board, Respondent's
23 worksite monitor, and Respondent's employers and supervisors to communicate regarding
24 Respondent's work status, performance, and monitoring.

25 For purposes of this section, "supervisors" shall include the Chief of Staff and Health or
26 Well Being Committee Chair, or equivalent, if applicable, when the Respondent has medical staff
27 privileges.

28 ///

1 11. BIOLOGICAL FLUID TESTING. Respondent shall immediately submit to
2 biological fluid testing, at Respondent's expense, upon request of the Board or its designee.
3 "Biological fluid testing" may include, but is not limited to, urine, blood, breathalyzer, hair
4 follicle testing, or similar drug screening approved by the Board or its designee. Respondent shall
5 make daily contact with the Board or its designee to determine whether biological fluid testing is
6 required. Respondent shall be tested on the date of the notification as directed by the Board or its
7 designee. The Board may order a Respondent to undergo a biological fluid test on any day, at
8 any time, including weekends and holidays. Except when testing on a specific date as ordered by
9 the Board or its designee, the scheduling of biological fluid testing shall be done on a random
10 basis. The cost of biological fluid testing shall be borne by the Respondent.

11 During the first year of probation, Respondent shall be subject to 52 to 104 random tests.
12 During the second year of probation and for the duration of the probationary term, up to five (5)
13 years, Respondent shall be subject to 36 to 104 random tests per year. Only if there has been no
14 positive biological fluid tests in the previous five (5) consecutive years of probation, may testing
15 be reduced to one (1) time per month. Nothing precludes the Board from increasing the number
16 of random tests to the first-year level of frequency for any reason.

17 Prior to practicing medicine, Respondent shall contract with a laboratory or service,
18 approved in advance by the Board or its designee, that will conduct random, unannounced,
19 observed, biological fluid testing and meets all of the following standards:

- 20 (a) Its specimen collectors are either certified by the Drug and Alcohol Testing Industry
21 Association or have completed the training required to serve as a collector for the United
22 States Department of Transportation.
- 23 (b) Its specimen collectors conform to the current United States Department of
24 Transportation Specimen Collection Guidelines.
- 25 (c) Its testing locations comply with the Urine Specimen Collection Guidelines published
26 by the United States Department of Transportation without regard to the type of test
27 administered.
- 28 (d) Its specimen collectors observe the collection of testing specimens.

- 1 (e) Its laboratories are certified and accredited by the United States Department of Health
2 and Human Services.
 - 3 (f) Its testing locations shall submit a specimen to a laboratory within one (1) business day
4 of receipt and all specimens collected shall be handled pursuant to chain of custody
5 procedures. The laboratory shall process and analyze the specimens and provide legally
6 defensible test results to the Board within seven (7) business days of receipt of the
7 specimen. The Board will be notified of non-negative results within one (1) business day
8 and will be notified of negative test results within seven (7) business days.
 - 9 (g) Its testing locations possess all the materials, equipment, and technical expertise
10 necessary in order to test Respondent on any day of the week.
 - 11 (h) Its testing locations are able to scientifically test for urine, blood, and hair specimens
12 for the detection of alcohol and illegal and controlled substances.
 - 13 (i) It maintains testing sites located throughout California.
 - 14 (j) It maintains an automated 24-hour toll-free telephone system and/or a secure on-line
15 computer database that allows the Respondent to check in daily for testing.
 - 16 (k) It maintains a secure, HIPAA-compliant website or computer system that allows staff
17 access to drug test results and compliance reporting information that is available 24 hours a
18 day.
 - 19 (l) It employs or contracts with toxicologists that are licensed physicians and have
20 knowledge of substance abuse disorders and the appropriate medical training to interpret
21 and evaluate laboratory biological fluid test results, medical histories, and any other
22 information relevant to biomedical information.
 - 23 (m) It will not consider a toxicology screen to be negative if a positive result is obtained
24 while practicing, even if the Respondent holds a valid prescription for the substance.
- 25 Prior to changing testing locations for any reason, including during vacation or other travel,
26 alternative testing locations must be approved by the Board and meet the requirements above.
- 27 The contract shall require that the laboratory directly notify the Board or its designee of
28 non-negative results within one (1) business day and negative test results within seven (7)

1 business days of the results becoming available. Respondent shall maintain this laboratory or
2 service contract during the period of probation.

3 A certified copy of any laboratory test result may be received in evidence in any
4 proceedings between the Board and Respondent.

5 If a biological fluid test result indicates Respondent has used, consumed, ingested, or
6 administered to himself or herself a prohibited substance, the Board shall order Respondent to
7 cease practice and instruct Respondent to leave any place of work where Respondent is practicing
8 medicine or providing medical services. The Board shall immediately notify all of Respondent's
9 employers, supervisors and work monitors, if any, that Respondent may not practice medicine or
10 provide medical services while the cease-practice order is in effect.

11 A biological fluid test will not be considered negative if a positive result is obtained while
12 practicing, even if the practitioner holds a valid prescription for the substance. If no prohibited
13 substance use exists, the Board shall lift the cease-practice order within one (1) business day.

14 After the issuance of a cease-practice order, the Board shall determine whether the positive
15 biological fluid test is in fact evidence of prohibited substance use by consulting with the
16 specimen collector and the laboratory, communicating with the licensee, his or her treating
17 physician(s), other health care provider, or group facilitator, as applicable.

18 For purposes of this condition, the terms "biological fluid testing" and "testing" mean the
19 acquisition and chemical analysis of a Respondent's urine, blood, breath, or hair.

20 For purposes of this condition, the term "prohibited substance" means an illegal drug, a
21 lawful drug not prescribed or ordered by an appropriately licensed health care provider for use by
22 Respondent and approved by the Board, alcohol, or any other substance the Respondent has been
23 instructed by the Board not to use, consume, ingest, or administer to himself or herself.

24 If the Board confirms that a positive biological fluid test is evidence of use of a prohibited
25 substance, Respondent has committed a major violation, as defined in section 1361.52(a), and the
26 Board shall impose any or all of the consequences set forth in section 1361.52(b), in addition to
27 any other terms or conditions the Board determines are necessary for public protection or to
28 enhance Respondent's rehabilitation.

1 12. SUBSTANCE ABUSE SUPPORT GROUP MEETINGS. Within thirty (30) days of
2 the effective date of this Decision, Respondent shall submit to the Board or its designee, for its
3 prior approval, the name of a substance abuse support group which he or she shall attend for the
4 duration of probation. Respondent shall attend substance abuse support group meetings at least
5 once per week, or as ordered by the Board or its designee. Respondent shall pay all substance
6 abuse support group meeting costs.

7 The facilitator of the substance abuse support group meeting shall have a minimum of three
8 (3) years' experience in the treatment and rehabilitation of substance abuse, and shall be licensed
9 or certified by the state or nationally certified organizations. The facilitator shall not have a
10 current or former financial, personal, or business relationship with Respondent within the last five
11 (5) years. Respondent's previous participation in a substance abuse group support meeting led by
12 the same facilitator does not constitute a prohibited current or former financial, personal, or
13 business relationship.

14 The facilitator shall provide a signed document to the Board or its designee showing
15 Respondent's name, the group name, the date and location of the meeting, Respondent's
16 attendance, and Respondent's level of participation and progress. The facilitator shall report any
17 unexcused absence by Respondent from any substance abuse support group meeting to the Board,
18 or its designee, within twenty-four (24) hours of the unexcused absence.

19 13. VIOLATION OF PROBATION CONDITION FOR SUBSTANCE ABUSING
20 LICENSEES. Failure to fully comply with any term or condition of probation is a violation of
21 probation.

22 A. If Respondent commits a major violation of probation as defined by section
23 1361.52, subdivision (a), of Title 16 of the California Code of Regulations, the Board shall take
24 one or more of the following actions:

25 (1) Issue an immediate cease-practice order and order Respondent to undergo a clinical
26 diagnostic evaluation to be conducted in accordance with section 1361.5, subdivision (c)(1), of
27 Title 16 of the California Code of Regulations, at Respondent's expense. The cease-practice
28 order issued by the Board or its designee shall state that Respondent must test negative for at least

1 a month of continuous biological fluid testing before being allowed to resume practice. For
2 purposes of determining the length of time a Respondent must test negative while undergoing
3 continuous biological fluid testing following issuance of a cease-practice order, a month is
4 defined as thirty calendar (30) days. Respondent may not resume the practice of medicine until
5 notified in writing by the Board or its designee that he or she may do so.

6 (2) Increase the frequency of biological fluid testing.

7 (3) Refer Respondent for further disciplinary action, such as suspension, revocation, or
8 other action as determined by the Board or its designee.

9 B. If Respondent commits a minor violation of probation as defined by section
10 1361.52, subdivision (c), of Title 16 of the California Code of Regulations, the Board shall take
11 one or more of the following actions:

12 (1) Issue a cease-practice order;

13 (2) Order practice limitations;

14 (3) Order or increase supervision of Respondent;

15 (4) Order increased documentation;

16 (5) Issue a citation and fine, or a warning letter;

17 (6) Order Respondent to undergo a clinical diagnostic evaluation to be conducted in
18 accordance with section 1361.5, subdivision (c)(1), of Title 16 of the California Code of
19 Regulations, at Respondent's expense;

20 (7) Take any other action as determined by the Board or its designee.

21 C. Nothing in this Decision shall be considered a limitation on the Board's authority
22 to revoke Respondent's probation if he or she has violated any term or condition of probation. If
23 Respondent violates probation in any respect, the Board, after giving Respondent notice and the
24 opportunity to be heard, may revoke probation and carry out the disciplinary order that was
25 stayed. If an Accusation, or Petition to Revoke Probation, or an Interim Suspension Order is filed
26 against Respondent during probation, the Board shall have continuing jurisdiction until the matter
27 is final, and the period of probation shall be extended until the matter is final.

28 ///

1 14. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the
2 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the
3 Chief Executive Officer at every hospital where privileges or membership are extended to
4 Respondent, at any other facility where Respondent engages in the practice of medicine,
5 including all physician and locum tenens registries or other similar agencies, and to the Chief
6 Executive Officer at every insurance carrier which extends malpractice insurance coverage to
7 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15
8 calendar days.

9 This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

10 15. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE
11 NURSES. During probation, Respondent is prohibited from supervising physician assistants and
12 advanced practice nurses.

13 16. OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules
14 governing the practice of medicine in California and remain in full compliance with any court
15 ordered criminal probation, payments, and other orders.

16 17. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations
17 under penalty of perjury on forms provided by the Board, stating whether there has been
18 compliance with all the conditions of probation.

19 Respondent shall submit quarterly declarations not later than 10 calendar days after the end
20 of the preceding quarter.

21 18. GENERAL PROBATION REQUIREMENTS.

22 Compliance with Probation Unit.

23 Respondent shall comply with the Board's probation unit.

24 Address Changes

25 Respondent shall, at all times, keep the Board informed of Respondent's business and
26 residence addresses, email address (if available), and telephone number. Changes of such
27 addresses shall be immediately communicated in writing to the Board or its designee. Under no
28 circumstances shall a post office box serve as an address of record, except as allowed by Business

1 and Professions Code section 2021, subdivision (b).

2 Place of Practice

3 Respondent shall not engage in the practice of medicine in Respondent's or patient's place
4 of residence, unless the patient resides in a skilled nursing facility or other similar licensed
5 facility.

6 License Renewal

7 Respondent shall maintain a current and renewed California physician's and surgeon's
8 license.

9 Travel or Residence Outside California

10 Respondent shall immediately inform the Board or its designee, in writing, of travel to any
11 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty
12 (30) calendar days.

13 In the event Respondent should leave the State of California to reside or to practice,
14 Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of
15 departure and return.

16 19. INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be
17 available in person upon request for interviews either at Respondent's place of business or at the
18 probation unit office, with or without prior notice throughout the term of probation.

19 20. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or
20 its designee in writing within 15 calendar days of any periods of non-practice lasting more than
21 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is
22 defined as any period of time Respondent is not practicing medicine as defined in Business and
23 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct
24 patient care, clinical activity or teaching, or other activity as approved by the Board. If
25 Respondent resides in California and is considered to be in non-practice, Respondent shall
26 comply with all terms and conditions of probation. All time spent in an intensive training
27 program which has been approved by the Board or its designee shall not be considered non-
28 practice and does not relieve Respondent from complying with all the terms and conditions of

1 probation. Practicing medicine in another state of the United States or Federal jurisdiction while
2 on probation with the medical licensing authority of that state or jurisdiction shall not be
3 considered non-practice. A Board-ordered suspension of practice shall not be considered as a
4 period of non-practice.

5 In the event Respondent's period of non-practice while on probation exceeds 18 calendar
6 months, Respondent shall successfully complete the Federation of State Medical Boards's Special
7 Purpose Examination, or, at the Board's discretion, a clinical competence assessment program
8 that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model
9 Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

10 Respondent's period of non-practice while on probation shall not exceed two (2) years.

11 Periods of non-practice will not apply to the reduction of the probationary term.

12 Periods of non-practice for a Respondent residing outside of California will relieve
13 Respondent of the responsibility to comply with the probationary terms and conditions with the
14 exception of this condition and the following terms and conditions of probation: Obey All Laws;
15 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or
16 Controlled Substances; and Biological Fluid Testing..

17 21. COMPLETION OF PROBATION. Respondent shall comply with all financial
18 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the
19 completion of probation. Upon successful completion of probation, Respondent's certificate shall
20 be fully restored.

21 22. VIOLATION OF PROBATION. Failure to fully comply with any term or condition
22 of probation is a violation of probation. If Respondent violates probation in any respect, the
23 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and
24 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,
25 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have
26 continuing jurisdiction until the matter is final, and the period of probation shall be extended until
27 the matter is final.

28 ///


1 23. LICENSE SURRENDER. Following the effective date of this Decision, if
2 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy
3 the terms and conditions of probation, Respondent may request to surrender his or her license.
4 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in
5 determining whether or not to grant the request, or to take any other action deemed appropriate
6 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent
7 shall within 15 calendar days deliver Respondent's wallet and wallet certificate to the Board or its
8 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject
9 to the terms and conditions of probation. If Respondent re-applies for a medical license, the
10 application shall be treated as a petition for reinstatement of a revoked certificate.

11 24. PROBATION MONITORING COSTS. Respondent shall pay the costs associated
12 with probation monitoring each and every year of probation, as designated by the Board, which
13 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of
14 California and delivered to the Board or its designee no later than January 31 of each calendar
15 year.

16 ACCEPTANCE

17 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
18 discussed it with my attorney, David M. Balfour Esq. I understand the stipulation and the effect it
19 will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and
20 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the
21 Decision and Order of the Medical Board of California.

22
23 DATED: 5/14/21


CHRIS HOLT, M.D.
Respondent

25 ///
26 ///
27 ///
28 ///

1 I have read and fully discussed with Respondent, Chris Holt, M.D., the terms and
2 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.
3 I approve its form and content.

4
5 DATED: May 19, 2021 David M Balfour
6 DAVID M. BALFOUR, ESQ.
7 Attorney for Respondent

8 **ENDORSEMENT**

9 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully
10 submitted for consideration by the Medical Board of California.

11 DATED: 5-20-2021 Respectfully submitted,
12 ROB BONTA
13 Attorney General of California
14 ALEXANDRA M. ALVAREZ
15 Supervising Deputy Attorney General
16 Alexandra M. Alvarez for
17 KAROLYN M. WESTFALL
18 Deputy Attorney General
19 Attorneys for Complainant

20 SD2019703019
21 Holt Stip Settlement and Disc Order - MBC-Osteopathic - stip.docx

22
23
24
25
26
27
28

Exhibit A

Accusation No. 800-2017-039244

1 XAVIER BECERRA
Attorney General of California
2 ALEXANDRA M. ALVAREZ
Supervising Deputy Attorney General
3 KAROLYN M. WESTFALL
Deputy Attorney General
4 State Bar No. 234540
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9465
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9
10 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
11 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA
12

13 In the Matter of the Accusation Against:

Case No. 800-2017-039244

14 **CHRIS HOLT, M.D.**
15 **3940 4th Ave., Ste. 140**
San Diego, CA 92103-3193

A C C U S A T I O N

16 **Physician's and Surgeon's Certificate**
17 **No. A 96213,**

18 Respondent.

19
20 **PARTIES**

21 1. William Prasifka (Complainant) brings this Accusation solely in his official capacity
22 as the Executive Director of the Medical Board of California, Department of Consumer Affairs
23 (Board).

24 2. On or about June 30, 2006, the Medical Board issued Physician's and Surgeon's
25 Certificate No. A 96213 to Chris Holt, M.D. (Respondent). The Physician's and Surgeon's
26 Certificate was in full force and effect at all times relevant to the charges brought herein and will
27 expire on February 28, 2022, unless renewed.

28 ///

1 (3) Be placed on probation and be required to pay the costs of probation
monitoring upon order of the board.

2 (4) Be publicly reprimanded by the board. The public reprimand may include a
3 requirement that the licensee complete relevant educational courses approved by the
board.

4 (5) Have any other action taken in relation to discipline as part of an order of
5 probation, as the board or an administrative law judge may deem proper.

6 ...

7 7. Section 2234 of the Code, states, in pertinent part:

8 The board shall take action against any licensee who is charged with
9 unprofessional conduct. In addition to other provisions of this article, unprofessional
conduct includes, but is not limited to, the following:

10 (a) Violating or attempting to violate, directly or indirectly, assisting in or
11 abetting the violation of, or conspiring to violate any provision of this chapter.

12 (b) Gross negligence.

13 (c) Repeated negligent acts. To be repeated, there must be two or more
14 negligent acts or omissions. An initial negligent act or omission followed by a
separate and distinct departure from the applicable standard of care shall constitute
repeated negligent acts.

15 ...

16 8. Unprofessional conduct under Business and Professions Code section 2234 is conduct
17 which breaches the rules or ethical code of the medical profession, or conduct which is
18 unbecoming a member in good standing of the medical profession, and which demonstrates an
19 unfitness to practice medicine. (*Shea v. Board of Medical Examiners* (1978) 81 Cal.App.3d 564,
20 575.)

21 9. Section 2238 of the Code states:

22 A violation of any federal statute or federal regulation or any of the statutes or
23 regulations of this state regulating dangerous drugs or controlled substances
constitutes unprofessional conduct.

24 10. Section 2239 of the Code states, in pertinent part:

25 (a) The use or prescribing for or administering to himself or herself, of any
26 controlled substance; or the use of any of the dangerous drugs specified in Section
27 4022, or of alcoholic beverages, to the extent, or in such a manner as to be dangerous
28 or injurious to the licensee, or to any other person or to the public, or to the extent that
such use impairs the ability of the licensee to practice medicine safely or more than
one misdemeanor or any felony involving the use, consumption, or
self-administration of any of the substances referred to in this section, or any

1 combination thereof, constitutes unprofessional conduct. The record of the
conviction is conclusive evidence of such unprofessional conduct.

2 ...

3 11. Section 11170 of the Health and Safety Code states: No person shall prescribe,
4 administer, or furnish a controlled substance for himself.

5 **SECTION 822 CAUSE FOR ACTION**

6 **(Mental Illness and/or Physical Illness Affecting Competency)**

7 12. Respondent is subject to action under section 822 of the Code in that his ability to
8 practice medicine safely is impaired due to a mental illness and/or physical illness affecting
9 competency, as more particularly alleged hereinafter:

10 13. Respondent has suffered from long standing Raynaud's phenomenon and episodic
11 arthritis symptoms dating back to childhood. He was diagnosed with Mixed Connective Tissue
12 Disease (MCTD) in or around the age of eighteen. Since that time Respondent has suffered from
13 chronic musculoskeletal back and joint pain.

14 14. In or around 2013, Respondent's symptoms were worsening and he was treating his
15 connective tissue disorder with high dose steroids.

16 15. Between in or around 2015, and in or around 2018, Respondent was receiving regular
17 prescriptions of opioids and benzodiazepines from various providers, including oxycodone,¹
18 Suboxone,² clonazepam,³ diazepam, and alprazolam.⁴

19 ¹ Oxycodone (brand name Oxycontin) is a Schedule II controlled substance pursuant to
20 Health and Safety Code section 11055, subdivision (b), and a dangerous drug pursuant to
Business and Professions Code section 4022. It is an opioid medication used to treat pain.

21 ² Suboxone (brand name for buprenorphine and naloxone), is a Schedule III controlled
22 substance pursuant to Health and Safety Code section 11056, subdivision (e), and a dangerous
23 drug pursuant to Business and Professions Code section 4022. It is an opioid medication used to
treat opioid addiction.

24 ³ Clonazepam (brand name Klonopin) is a Schedule IV controlled substance pursuant to
25 Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to
Business and Professions Code section 4022. It is an anti-anxiety medication in the
benzodiazepine family.

26 ⁴ Alprazolam (brand name Xanax) is a Schedule IV controlled substance pursuant to
27 Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to
28 Business and Professions Code section 4022. It is an anti-anxiety medication in the
benzodiazepine family.

1 16. Between in or around 2016, and in or around 2020, Respondent regularly self-
2 prescribed metoprolol.⁵

3 17. Between in or around 2016, and in or around 2019, Respondent regularly self-
4 prescribed prednisone.⁶

5 18. On or about April 22, 2016, Respondent sought a Suboxone evaluation from E.C.,
6 M.D. (Dr. E.C.). At that time, Respondent reported having been prescribed oxycodone one year
7 earlier, but expressed concern that the dose had gradually escalated and he experienced
8 withdrawal when he ran out. Respondent's desire was to use Suboxone to taper off opiates
9 completely. Dr. E.C. diagnosed Respondent with opioid dependence and prescribed him with a
10 one month supply of Suboxone 8 mg-2 mg sublingual film.

11 19. On or about May 27, 2016, Respondent self-prescribed testosterone cypionate.⁷

12 20. On or about June 2, 2016, Respondent self-prescribed Axiron.⁸

13 21. On or about December 23, 2016, Respondent established care with J.C., M.D. (Dr.
14 J.C.) as his primary care physician. At that time, Respondent had complaints of chronic pain and
15 hypogonadism from long-term opiate use. Dr. J.C. diagnosed Respondent with chronic pain, and
16 prescribed him Oxycontin and oxycodone. Respondent received treatment and monthly
17 prescriptions from Dr. J.C. until in or around June 2017. In or around December 2017 through in
18 or around March 2018, Respondent also received monthly benzodiazepine prescriptions from Dr.
19 J.C.

20 ///

21 _____
22 ⁵ Metoprolol is a beta-blocker medication used to treat high blood pressure, and a
23 dangerous drug pursuant to Business and Professions Code section 4022.

24 ⁶ Prednisone is a corticosteroid medication used to treat inflammation, and a dangerous
25 drug pursuant to Business and Professions Code section 4022.

26 ⁷ Testosterone cypionate (brand name Depo-Testosterone) is a Schedule III controlled
27 substance pursuant to Health and Safety Code section 11056, subdivision (f), and a dangerous
28 drug pursuant to Business and Professions Code section 4022. It is an injectable medication used
on males with low testosterone.

⁸ Axiron is a Schedule III controlled substance pursuant to Health and Safety Code section
11056, subdivision (f), and a dangerous drug pursuant to Business and Professions Code section
4022. It is a topical testosterone medication used on males with low testosterone.

1 22. On or about March 20, 2017, while still under the care of Dr. J.C., Respondent sought
2 a pain management consultation from F.P., M.D. (Dr. F.P.), during which he admitted taking
3 significant amounts of opiates. Dr. F.P. diagnosed Respondent with opioid dependence,
4 encouraged him to go onto Suboxone, and prescribed him a courtesy 30-day prescription of
5 oxycodone and Oxycontin.

6 23. On or about June 28, 2017, Respondent established care with psychiatrist, A.R., M.D.
7 (Dr. A.R.). He sought a Suboxone prescription not for pain control, but to get him off opioids
8 without withdrawal symptoms. At that time, he admitted occasionally taking extra oxycodone
9 when he was up late and experiencing withdrawals. Dr. A.R. diagnosed Respondent with opioid
10 use disorder and unspecified anxiety disorder, and prescribed him Suboxone 8-2 mg sublingual
11 film. Dr. A.R. maintained Respondent on that monthly prescription of Suboxone until on or
12 about September 24, 2018, when he reduced his Suboxone dose by half. Between in or around
13 March 2018, and in or around May 2018, Dr. A.R. also prescribed Respondent monthly
14 prescriptions of alprazolam and diazepam,⁹ and diagnosed him with Bipolar II disorder in August
15 2019.

16 24. Between in or around June 2016, and in or around June 2017, while he was receiving
17 treatment from other providers, Respondent regularly self-prescribed bupropion¹⁰ and
18 lamotrigine.¹¹ During that same time frame, he also received regular courtesy prescriptions of
19 clonazepam from his supervisor, A.Z., M.D., who did not maintain treatment records.

20 25. On or about December 11, 2017, Respondent appeared drunk or under the influence
21 while at work. On that date, he had an unsteady gait, was unstable and incoherent, and patients
22 complained he was falling asleep during their visit. Respondent does not recall this event,

23 ⁹ Diazepam (brand name Valium) is a Schedule IV controlled substance pursuant to
24 Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to
25 Business and Professions Code section 4022. It is an anti-anxiety medication in the
benzodiazepine family.

26 ¹⁰ Bupropion (brand name Wellbutrin) is an antidepressant medication, and a dangerous
drug pursuant to Business and Professions Code section 4022.

27 ¹¹ Lamotrigine (brand name Lamictal) is an anticonvulsant mood stabilizing medication,
28 and a dangerous drug pursuant to Business and Professions Code section 4022.

1 specifically, but alleges to have had a syncopal episode after he took a second dose of metoprolol
2 earlier than normal due to experiencing bad palpitations. He claimed this had never happened to
3 him before, and even though his supervisor had to awaken him at his desk, he did not seek any
4 follow-up care with his cardiologist after the event.

5 26. On or about March 20, 2018, Respondent provided a voluntary urine sample to A.M.,
6 an investigator for the Board (Investigator A.M.), agreed to undergo voluntary mental and
7 physical evaluations, and provided various releases for his medical records. His urine sample later
8 tested positive for buprenorphine.

9 27. On or about June 8, 2018, Respondent self-prescribed clonidine.¹²

10 28. On or about August 20, 2108, Respondent voluntarily submitted to a mental
11 evaluation by Board appointed psychiatrist, Steven A. Ornish, M.D. (Dr. Ornish). After
12 conducting an extensive review of materials and a face-to-face evaluation, Dr. Ornish opined that
13 Respondent suffers from, among other things, an opioid use disorder, a history of opioid use
14 withdrawal, and an unspecified anxiety disorder. He further concluded that Respondent was
15 unable to practice medicine safely at that time as a result of these diagnoses, without appropriate
16 monitoring. Dr. Ornish identified that appropriate monitoring would include pharmacologic
17 management by someone other than Dr. A.R., reconsideration of his current medication regimen,
18 receipt of all psychotropic and opioid medications from his treating psychiatrist, random urine
19 drug screens, participation in an out-patient drug treatment program, continued tapering of his
20 Suboxone, and non-opioid treatment for future flare-ups of pain.

21 29. On or about August 22, 2018, Respondent voluntarily submitted to a physical
22 evaluation by Board appointed family medicine physician, Lee P. Ralph, M.D. (Dr. Ralph). After
23 conducting an extensive review of materials and a face-to-face evaluation, Dr. Ralph opined that
24 Respondent suffers from, among other things, MCTD with chronic hand arthralgias and
25 Raynaud's syndrome, and a history of opioid use disorder. He found Respondent's main medical
26 issue to be his chronic pain related to his MCTD, for which he requires chronic opioid use. Dr.

27
28 ¹² Clonidine is a sedative antihypertensive medication used to treat high blood pressure,
and a dangerous drug pursuant to Business and Professions Code section 4022.

1 Ralph further concluded that Respondent was unable to practice medicine safely at that time as a
2 result of these diagnoses, without appropriate management and oversight of his Suboxone use by
3 a pain medicine physician. Dr. Ralph identified that appropriate management would include
4 monthly or bi-monthly monitoring, regular checking of the CURES database, periodic urine drug
5 screens, and physical and mental health screenings and assessments at regular intervals.

6 30. Between on or about August 1, 2019, and on or about July 14, 2020, while under the
7 care of his psychiatrist, Dr. A.R., Respondent regularly self-prescribed gabapentin,¹³ olanzapine,¹⁴
8 and quetiapine.¹⁵

9 31. On or about May 22, 2020, during his subject interview with Investigator A.M.,
10 Respondent admitted that he still takes Suboxone, and agreed that he suffers from opioid
11 dependency, a history of opioid withdrawals, and an anxiety disorder. Respondent further
12 admitted that he has never received outpatient treatment, does not currently see a pain specialist,
13 and has not attempted to taper his Suboxone since 2018.

14 32. On or about July 10, 2020, after reviewing additional records, including Respondent's
15 current medical records from Dr. A.R., current CURES report, and the recording and transcript
16 from his subject interview, Dr. Ornish's previous opinions rendered were unchanged. Dr. Ornish
17 concluded that the observed behavior of Respondent on or about December 11, 2017, was not a
18 "syncopal episode" as he contends, but rather, is best explained by a physician impaired at work
19 from over-medication from benzodiazepines (clonazepam and alprazolam), combined with an
20 opioid (Suboxone) - all of which he filled on or around December 11, 2017. Dr. Ornish opined
21 that Respondent suffers from, among other things, an opioid use disorder, a history of opioid use
22 withdrawal, and an unspecified anxiety disorder. Dr. Ornish further opined that Respondent is
23

24 ¹³ Gabapentin is anticonvulsant nerve pain medication, and a dangerous drug pursuant to
Business and Professions Code section 4022.

25 ¹⁴ Olanzapine (brand name Zyprexa) is an antipsychotic medication used to treat mental
26 disorders, including schizophrenia and bipolar disorder, and is a dangerous drug pursuant to
Business and Professions Code section 4022.

27 ¹⁵ Quetiapine (brand name Seroquel) is an antipsychotic medication used to treat mental
28 disorders, including schizophrenia and bipolar disorder, and is a dangerous drug pursuant to
Business and Professions Code section 4022.

1 unable to practice medicine safely at this time as a result of these diagnoses, and that his
2 continued practice of medicine without appropriate monitoring will endanger the public health,
3 safety, and welfare.

4 33. On or about July 28, 2020, after reviewing additional records, including Respondent's
5 current medical records from Dr. A.R., current CURES report, and the recording and transcript
6 from his subject interview, Dr. Ralph concluded that Respondent is not taking Suboxone for pain
7 management as he previously believed, but more so for his opioid use disorder. Dr. Ralph is
8 concerned that Respondent is not being closely monitored by his prescribing physician, Dr. A.R.,
9 and opined that Respondent suffers from a chronic pain syndrome and an opioid use disorder, and
10 requires chronic narcotic medications. Dr. Ralph further opined that Respondent is unable to
11 practice medicine safely at this time as a result of these diagnoses, and that his continued practice
12 of medicine without appropriate management and oversight of his Suboxone use by his
13 prescribing physician will endanger the public health, safety, and welfare.

14 **FIRST CAUSE FOR DISCIPLINE**

15 **(Prescribing or Administering Controlled Substances to Himself)**

16 34. Respondent has subjected his Physician's and Surgeon's Certificate No. A 96213 to
17 disciplinary action under sections 2227, and 2234, as defined by section 2239, subdivision (a), of
18 the Code, in that he has prescribed or administered controlled substances to himself, as more
19 particularly alleged in paragraphs 12 through 33, above, which are hereby incorporated by
20 reference and realleged as if fully set forth herein.

21 **SECOND CAUSE FOR DISCIPLINE**

22 **(Violation of State Laws Regulating Dangerous Drugs and/or Controlled Substances)**

23 35. Respondent has further subjected his Physician's and Surgeon's Certificate No.
24 A 96213 to disciplinary action under sections 2227 and 2234, as defined by section 2238, of the
25 Code, in that he has violated a state law or laws regulating dangerous drugs and/or controlled
26 substances, as more particularly alleged hereinafter:

27 A. Paragraphs 12 through 33 above, are hereby incorporated by reference and
28 realleged as if fully set forth herein;

1 B. Respondent has administered controlled substances to himself, in violation of
2 Health and Safety Code section 11170, and section 2339, subdivision (a), of the
3 Code.

4 **THIRD CAUSE FOR DISCIPLINE**

5 **(Gross Negligence)**

6 36. Respondent has further subjected his Physician's and Surgeon's Certificate No.
7 A 96213 to disciplinary action under sections 2227 and 2234, as defined by section 2234,
8 subdivision (b), of the Code, in that he was grossly negligent as more particularly alleged
9 hereinafter:

- 10 A. Paragraphs 12 through 33, above, are hereby incorporated by reference and
- 11 realleged as if fully set forth herein;
- 12 B. Self-prescribing olanzapine in or around 2019;
- 13 C. Self-prescribing quetapine between in or around 2019 through in or around
- 14 2020;
- 15 D. Self-prescribing clonidine on or about June 8, 2018;
- 16 E. Self-prescribing lamotrigine between in or around 2016 and in or around 2017;
- 17 F. Self-prescribing gabapentin in or around 2019; and
- 18 G. Self-prescribing bupropion in or around 2016 through in or around 2019.

19 **FOURTH CAUSE FOR DISCIPLINE**

20 **(Repeated Negligent Acts)**

21 37. Respondent has further subjected his Physician's and Surgeon's Certificate No.
22 A 96213 to disciplinary action under sections 2227 and 2234, as defined by section 2234,
23 subdivision (c), of the Code, in that he committed repeated negligent acts as more particularly
24 alleged in paragraphs 12 through 33, and 36, above, which are hereby incorporated by reference
25 and realleged as if fully set forth herein.

26 ///
27 ///
28 ///

1 **FIFTH CAUSE FOR DISCIPLINE**

2 **(General Unprofessional Conduct)**

3 38. Respondent has further subjected his Physician's and Surgeon's Certificate No.
4 A 96213 to disciplinary action under sections 2227 and 2234 of the Code, in that he has engaged
5 in conduct which breaches the rules or ethical code of the medical profession, or conduct which is
6 unbecoming to a member in good standing of the medical profession, and which demonstrates an
7 unfitness to practice medicine, as more particularly alleged in paragraphs 12 through 33, above,
8 which are hereby incorporated by reference as if fully set forth herein.

9 **PRAYER**

10 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
11 and that following the hearing, the Medical Board of California issue a decision:

12 1. Revoking or suspending Physician's and Surgeon's Certificate No. A 96213, issued
13 to Respondent, Chris Holt, M.D.;

14 2. Revoking, suspending or denying approval of Respondent, Chris Holt, M.D.'s
15 authority to supervise physician assistants and advanced practice nurses;


16 3. Ordering Respondent, Chris Holt, M.D., if placed on probation, to pay the Board the
17 costs of probation monitoring;

18 4. Taking action as authorized by section 822 of the Code as the Board, in its discretion,
19 deems necessary and proper;

20 5. Ordering Respondent, Chris Holt, M.D., if placed on probation, to disclose the
21 disciplinary order to patients pursuant to section 2228.1 of the Code; and

22 6. Taking such other and further action as deemed necessary and proper.

23
24 DATED: Dec. 7, 2020

25 
26 WILLIAM PRASIFKA
27 Executive Director
28 Medical Board of California
Department of Consumer Affairs
State of California
Complainant

SD2019703019
82601145.docx